• English
  • العربية
  • 中文
  • Français
  • Русский
  • Español

You are here

Development of Kits for 99mTc Radiopharmaceuticals for Infection Imaging

English IAEA-TECDOC-1414 92-0-111304-8
120 15.00 2004

Download PDF (1.95 MB)


Development of Tc-99m labelling strategies can be useful in the preparation of infection imaging agents by laboratories in Member States. With techniques that were developed for the testing of label stability in vitro and in vivo, with the laboratories participating in the project becoming proficient in labelling the chosen molecules with Tc-99m using a variety of techniques, and with in vivo and in vitro quality assurance measurements standardized by all participants and applied, Tc-99m agents were viewed as reliably labelled. Additionally, with the identification of Tc-99m ubiquicidin peptide 29–41 as a radiolabelled agent with potential clinical utility, the project has made a major contribution to nuclear medicine by providing the first convenient Tc-99m labelled ‘specific’ infection imaging agent.

More Information on reusing IAEA copyright material.

How to order

Ordering Locally

Please use the following links for an up-to-date list of IAEA distributors:

Distributors of IAEA Publications

Orders and requests for information may also be addressed to:

Marketing and Sales Unit
International Atomic Energy Agency
Vienna International Centre
PO Box 100, A-1400 Vienna,

Tel.: +43 1 2600 22529, +43 1 2600 22530
Fax: +43 1 2600 29302
Email: sales.publications@iaea.org

Download order form


  1. Employment
  2. Women
  3. Press

Stay in touch